<DOC>
	<DOCNO>NCT01874457</DOCNO>
	<brief_summary>On previous study conduct Brazil . The MMR vaccine 2 different producer mumps seroconversion much low ( 71 % ) expect 95 % , accord package insert . This could indicate substantial proportion child protect MMR dose .</brief_summary>
	<brief_title>Serological Study Children 12 23 Months Vaccinated With MMR ( Measles , Mumps Rubella )</brief_title>
	<detailed_description>Given consider : ( 1 ) future clinical study MMR vaccine produce entirely Bio-Manguinhos/Fiocruz technology transfer GlaxoSmithKline ( GSK ) , ( 2 ) importance National Immunization Program ( NIP ) provide population MMR vaccine ensure high protection mumps , similar occurs measles rubella component , consider essential conduct preliminary immunogenicity assessment MMR vaccine produce BioManguinhos .</detailed_description>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Mumps</mesh_term>
	<criteria>Children sex ; Age 12 month 23 month 29 day ; Child good health , significant past medical history ; Have complete blood sample vaccination ; Have vaccinate MMR . Agreement parents/tutors child 's participation study signing Informed Consent Form ( ICF ) ; Parents/Tutors provide name , address , telephone number information contact necessary ; Parents/Tutors able understand risk experiment , although minimal ; Parents/Tutors able understand sign inform consent form . Availability return collect postvaccination sample . Exclusion criterion : Children history measles , rubella / mumps . Having receive MMR vaccine previously , document vaccination card . Having receive transfusion blood blood product , include immunoglobulin , within last 12 month . Skin lesion sit venipuncture . Child subject abnormal bleeding injection . Use within 6 month corticosteroid ( exclude topical aerosol ) immunosuppressant .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>